Healthcare & Life Sciences
TriArm Therapeutics
United States
series-a
series-a
Stage
1
Investors
About
TriArm Therapeutics develops autologous, non-viral manufacturing technologies for CAR-T and other cell therapies to increase yield of immune‑naïve, potent and persistent T cells, shorten vein‑to‑vein delivery times, reduce costs, and mitigate cytokine storm risk.
Explore TriArm Therapeutics's full profile on Brouky
Funding rounds, investor list, and risk signals — unlock with a subscription.